A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

ConditionParkinson Disease

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age40-75

SponsorNuwacell Biotechnologies Co., Ltd.

About this trial

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.

Eligibility criteria

Qualifiers

Ages between 40 and 75 years;

Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;

Disease history over 5 years;

Stable dose of dopamine treatment;

Disqualifiers

Patients who have previously undergone brain surgery;

Past use of stem cell therapy or participation in stem cell clinical research;

Cognitive impairment;

History of mental disorders;

Trial design

Treatments tested in this trial

Allogeneic dopaminergic neural precursor cell(NCR201)

Treatment groups

48 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Nuwacell Biotechnologies Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov